Physicians, pharmacists and take-home naloxone: What practices? The SINFONI study.

Autor:	Duval M; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France., Aquizerate A; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France., Jaulin E; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France., Rousselet M; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France; Nantes Université, Université Tours, CHU Nantes, CHU Tours, Inserm, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, 44000 Nantes, France., Kuhn E; Nantes Université, CHU de Nantes, UIC22, Service Douleur Soins Palliatifs et Soins de Support, 44093 Nantes, France; Réseau Douleur de l'Ouest (REDO), 44000 Nantes, France., Guilleminot A; Union Régionale des Professionnels de Santé Libéraux (URPS) Pharmaciens Pays de la Loire, 44200 Nantes, France., Nicolleau I; Conseil Régional de l'Ordre des Pharmaciens (CROP) Pays de la Loire, 44004 Nantes, France., Pele S; Structure Régionale d'Appui et d'Expertise (SRAE) en Addictologie des Pays de la Loire, 44200 Nantes, France., Herault T; Union Régionale des Médecins Libéraux (URML) Pays de la Loire, 44230 Saint-Sébastien-sur-Loire, France., Artarit P; Direction régionale du Service médical (DRSM) des Pays de la Loire, 44000 Nantes, France., Soulidou-Jacques E; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France., Laforgue EJ; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France; Nantes Université, Université Tours, CHU Nantes, CHU Tours, Inserm, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, 44000 Nantes, France., Victorri-Vigneau C; Nantes Université, CHU de Nantes, Centre d'Évaluation et d'Information sur la Pharmacodépendance-Addictovigilance (CEIP-A), Service de Pharmacologie Clinique, 44000 Nantes, France; Nantes Université, Université Tours, CHU Nantes, CHU Tours, Inserm, MethodS in Patients-centered outcomes and HEalth Research, SPHERE, 44000 Nantes, France. Electronic address: caroline.vigneau@chu-nantes.fr.
Jazyk:	angličtina
Zdroj:	Therapie [Therapie] 2024 Nov-Dec; Vol. 79 (6), pp. 623-633. Date of Electronic Publication: 2024 Jul 11.
DOI:	10.1016/j.therap.2024.07.001
Abstrakt:	Objective: For several years, both the French Addictovigilance Network and French health authorities have consistently emphasized the need to provide opioid users with take-home naloxone (THN), the specific antidote for opioid overdoses. In March 2022, the French Health Authority recommended systematically assessing the appropriateness of prescribing THN to all opioid users, regardless of the context, and identified 8 high-risk situations. However, at present, THN distribution remains limited, particularly among primary care healthcare professionals. This study, conducted by the Pays de la Loire Centre for Evaluation and Information on Drug Dependence-Addictovigilance and supported by the Regional Health Agency, aims to explore healthcare professionals' practices and perceptions of these high-risk situations. Methods: An ad-hoc questionnaire was distributed via mail by the project's regional institutional partners to the target healthcare professionals: pharmacists, general practitioners (GPs), physicians practicing in specialities other than general medicine (SPs: algologists, psychiatrists and addictologists). It was completed online from 20/10/2022 to 30/12/2022. Results: Out of the 355 participants (158 pharmacists, 167 GPs and 30 SPs), nearly all were managing patients on opioids. In total, 47.7% of physicians and 27.8% of pharmacists reported experiencing difficulties in dealing with the risk of overdose when prescribing or dispensing opioids to their patients. In the 12months preceding the study, only 8 pharmacists and 34 physicians had prescribed/dispensed THN, primarily due to a lack of awareness of its existence (52% of pharmacists and 72% of physicians) and challenges in addressing the eight overdose risk situations listed by the HAS (ranging from 54% to 83% for all professionals). The best-trained healthcare professionals were those who prescribed the most THN (P<0.001). Conclusion: The identification of barriers related to THN distribution in the regional SINFONI study, conducted among primary care healthcare professionals managing patients on opioids, highlights the need to develop a training tool specifically tailored for these professionals. (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu